COVID-19
Conditions
Keywords
COVID-19, real world evaluation on COVID-19 burden
Brief summary
The purpose of this study is to learn about: * effects of living with COVID-19 and * how effective is nirmatrelvir-ritonavir in treating COVID-19. This is a study of two groups of COVID-19 patients in Taiwan. In Group 1 the below participants were included in the study: * Patients of all ages. * Patients who were confirmed to have COVID-19 infection between 01 January 2021 and 31 December 2021. * Cases of patients registered in the databases. In Group 2 the below participants were included in the study: * Participants who are 12 years or older. * Confirmed to have COVID-19 between 01 January 2022 and 31 December 2022. Nirmatrelvir-ritonavir is taken by mouth and is used to treat COVID-19. The study will look at: * the nature of Covid-19 disease. * as well as the experiences of people receiving the nirmatrelvir-ritonavir. This study will help to: * understand what type of patients will need to be admitted to hospitals. * see severe results due to COVID 19 infection. * have more knowledge on the use of nirmatrelvir/ritonavir on COVID-19.
Interventions
DRUGSoC
COVID-19 treatment as per government guidance
OTHERDisease description
No intervention
Sponsors
Pfizer
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
0 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Cohort 1: Inclusion Criteria: * Patients of all ages * Patients with a diagnosis of COVID-19 infection between 01 January 2021 and 31 December 2021 * Cases of patients registered in the databases
Exclusion criteria
* Patients without COVID-19 diagnosis Cohort 2: Inclusion Criteria: * ≥12 years of age * Have COVID-19 diagnosis with international classification of diseases (ICD) code between 01 January 2022 and 31 December 2022
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cohort 1: Demographical Characteristics of Participants with a Diagnosis of COVID-19 That Required Intensive Care Unit (ICU) | 01 January 2021 to 31 December 2021 |
| Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Required ICU | 01 January 2021 to 31 December 2021 |
| Cohort 1: Demographical Characteristics of Participants with a Diagnosis of COVID-19 That Did Not Require ICU | 01 January 2021 to 31 December 2021 |
| Cohort 1: Comorbidities of Participants with a diagnosis of COVID-19 that did not require ICU | 01 January 2021 to 31 December 2021 |
| Cohort 1: Demographical Characteristics of Participants with a diagnosis of COVID-19 that required ICU | 01 January 2021 to 31 December 2021 |
| Cohort 1: Demographical Characteristics of Participants with a Diagnosis of COVID-19 That Required Ventillatory Support | 01 January 2021 to 31 December 2021 |
| Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Required Ventillatory Support | 01 January 2021 to 31 December 2021 |
| Cohort 1: Demographical Characteristics of Participants with a Diagnosis of COVID-19 That Did Not Require Ventillatory Support | 01 January 2021 to 31 December 2021 |
| Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Did Not Require Ventillatory Support | 01 January 2021 to 31 December 2021 |
| Cohort 1: Demographics of Participants with a Diagnosis of COVID-19 That Had a Fatal Outcome | 01 January 2021 to 31 December 2021 |
| Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Had a Fatal Outcome | 01 January 2021 to 31 December 2021 |
| Cohort 1: Demographics of Participants with a Diagnosis of COVID-19 That Did Not Have a Fatal Outcome | 01 January 2021 to 31 December 2021 |
| Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Did Not Have a Fatal Outcome | 01 January 2021 to 31 December 2021 |
| Cohort 2: Characteristics Associated with Patients Receiving nirmatrelvir/ritonavir vs Patients Not Receiving nirmatrelvir/ritonavir | 01 January 2022 to 31 December 2022 |
Secondary
| Measure | Time frame |
|---|---|
| Cohort 1: Demographics of Participants with a Diagnosis of COVID-19 That Required Hospital Admission | 01 January 2021 to 31 December 2021 |
| Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Required Hospital Admission | 01 January 2021 to 31 December 2021 |
| Cohort 1: Demographics of Participants with a Diagnosis of COVID-19 That Did Not Require Hospital Admission | 01 January 2021 to 31 December 2021 |
| Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Did Not Require Hospital Admission | 01 January 2021 to 31 December 2021 |
| Cohort 1: Incidence Proportion of ICU Admissions Among COVID-19 Patients Requiring Hospitalization Per Age Range | 01 January 2021 to 31 December 2021 |
| Cohort 1: Clinical Characteristics Associated to ICU Admission Among Hospitalized COVID-19 Patients | 01 January 2021 to 31 December 2021 |
| Cohort 1: Risk Factors Associated to ICU Admission Among Hospitalized COVID-19 Patients | 01 January 2021 to 31 December 2021 |
| Cohort 1: Clinical Characteristics Associated to Ventilatory Support Among Hospitalized COVID-19 Patients | 01 January 2021 to 31 December 2021 |
| Cohort 1: Risk Factors Associated to Ventilatory Support Among Hospitalized COVID-19 Patients | 01 January 2021 to 31 December 2021 |
| Cohort 1: Mortality Rate Associated to Ventilatory Support Among Hospitalized COVID-19 Patients | 01 January 2021 to 31 December 2021 |
| Cohort 1: Average Length of Stay (LOS) of Hospitalized COVID-19 Patients | 01 January 2021 to 31 December 2021 |
| Cohort 2: Incidence for severe COVID-19 Overall | 01 January 2022 to 31 December 2022 |
| Cohort 2: Incidence for severe COVID-19 By Risk Group | 01 January 2022 to 31 December 2022 |
| Cohort 2: Incidence for severe COVID-19 By Time Period | 01 January 2022 to 31 December 2022 |
| Cohort 2: Relative Risk for severe COVID-19 Overall | 01 January 2022 to 31 December 2022 |
| Cohort 2: Relative Risk for severe COVID-19 By Risk Group | 01 January 2022 to 31 December 2022 |
| Cohort 2: Relative Risk for severe COVID-19 By Time Period | 01 January 2022 to 31 December 2022 |
Countries
Taiwan
Contacts
STUDY_DIRECTORPfizer CT.gov Call Center
Pfizer
Outcome results
None listed